Joint Ventures and Other Equity Method Affiliates (Tables)

12 Months Ended

Dec. 31, 2013

Equity Method Investments and Joint Ventures [Abstract]

Equity income from affiliates reflects the performance of the Company’s joint ventures and other equity method affiliates and was comprised of the following:



Years Ended December 31	2013		2012		2011
AstraZeneca LP	$	352	$	621	$	574
Other ⁽¹⁾	52		21		36
	$	404	$	642	$	610

⁽¹⁾ Primarily reflects results from Sanofi Pasteur MSD and Johnson & Johnson°Merck Consumer Pharmaceuticals Company (which was disposed of on September 29, 2011).

Summarized Financial Information for AZLP

Summarized financial information for AZLP is as follows:



Years Ended December 31	2013		2012		2011
Sales	$	4,611	$	4,694	$	4,659
Materials and production costs	2,222		2,177		2,023
Other expense, net	1,175		1,312		1,392
Income before taxes ⁽¹⁾	$	1,214	$	1,205	$	1,244



December 31	2013		2012
Current assets	$	4,832	$	3,662
Noncurrent assets	182		206
Current liabilities	3,958		3,145


⁽¹⁾	Merck’s partnership returns from AZLP are generally contractually determined as noted above and are not based on a percentage of income from AZLP, other than with respect to Merck’s 1% limited partnership interest.

Summarized Financial Information for Affiliates (Excluding AZLP)

Summarized information for those affiliates (excluding AZLP disclosed separately above) is as follows:



Years Ended December 31	2013		2012		2011⁽¹⁾
Sales	$	1,326	$	1,295	$	1,331
Materials and production costs	581		573		584
Other expense, net	691		705		642
Income before taxes	54		17		105



December 31	2013		2012
Current assets	$	1,486	$	971
Noncurrent assets	149		112
Current liabilities	456		480
Noncurrent liabilities	154		97

⁽¹⁾ Includes information for the JJMCP joint venture until its divestiture on September 29, 2011.